AUTHORS
Shenmiao Yang, PhD, Donglu Zhao, PhD2, Rong Wei3, Rui Zhang, MD4, Zhenshu Xu5, Lihong Liu6, Mingzhi Zhang, MD7, Xutao Guo, MD, PhD8, Kaiyang Ding, MD9, Ou Bai, MD10, Jia Wei, MD, PhD11, Guohui Cui12, Fei Li13, Xiaojun Huang, MD, PhD14, Jun Ma, MD15
AFFILIATIONS
1 Peking University People‘s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Treatment of Hematologic Disease, Beijing, China
2 Harbin Institute of Hematology and Oncology, Harbin, China
3 Peking University People‘s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Treatment of Hematologic Disease, Beijing, China
4 The First Hospital of China Medical University, Shenyang, China
5 Fujian Medical University Union Hospital, Fuzhou, China
6 The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China
7 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Anhui Provincial Cancer Hospital, Hefei, China
10 The First Hospital of Jilin University, Changchun, China
11 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 The First Affiliated Hospital of Nanchang University, Nanchang, China
14 Peking University People‘s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Treatment of Hematologic Disease, Beijing, China
15 Harbin Institute of Hematology and Oncology, Harbin, China
ABSTRACT
Background
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has been progressively incorporating chemotherapy-free, fixed-duration regimens, particularly those involving BCL-2 inhibitors, which offer clear advantages in reducing long-term toxicity, lowering economic burden, and delaying drug resistance. With BCL-2 inhibitors currently approved in China, there is a realistic foundation for the clinical implementation of time-limited combination therapies. However, the real-world adoption of fixed-duration therapy continues to face major obstacles, including insufficient reimbursement, limited access, and inadequate awareness of its efficacy and strategic value among both physicians and patients. This study focuses on this central issue and systematically evaluates perceptions, preference discordance, and barriers to fixed-duration therapy from both physician and patient perspectives.
Methods
A multicenter, cross-sectional survey was conducted across China in June 2026. The patient survey (n=453) covered 30 provinces and collected demographics, disease characteristics, current treatment regimens, Hospital Anxiety and Depression Scale (HADS) and Comprehensive Score for Financial Toxicity (COST) data, as well as acceptability of fixed-duration therapy. The physician survey (n=109) from 29 hospitals collected demographics, practice patterns, acceptance of fixed-duration therapy, rationales for recommendation, and key concerns. Statistical analyses included chi-square, Fisher's exact, multivariable logistic regression, and Wilcoxon rank-sum tests.
Results
A total of 453 patients were enrolled (85% with CLL; median age, 56 years; 57% non-local residents; 53% with comorbidities). Of these, 27.3% had not initiated treatment, 62.7% were receiving BTK inhibitors, and 9.9% were on BCL-2 inhibitors. While 92.9% preferred fixed-duration therapy, only 9.3% favored continuous treatment. Patients in central and western China reported significantly greater financial toxicity than those in eastern China (median COST score, 19.0 vs. 21.0; P = 0.008). Moderate-to-severe anxiety and depression were observed in 28.0% and 22.5% of patients, respectively, with anxiety levels significantly higher in central and western regions (median score, 10.0 vs. 9.0; P = 0.0004). Notably, 64.5% had an annual household income below 100,000 RMB (~14,800 USD), and 93.1% depended on basic medical insurance or government-funded medical care, underscoring that economic burden poses a major barrier to selecting and accessing fixed-duration therapy.
A total of 109 physicians were surveyed (95.4% hematologists; 51.4% with senior titles). Only 23.9% preferred fixed-duration therapy as first-line treatment, compared with 47.7% favoring continuous therapy and 28.4% adopting a case-by-case approach. Efficacy (81.7% ranked in the top two), economic burden (42.2%), and guideline recommendations (35.8%) were the primary determinants of regimen selection. Regarding barriers to fixed-duration therapy, drug access and reimbursement (53.2%), tumor lysis syndrome concerns (51.4%), myelosuppression risk (46.8%), and uncertainty about durability after treatment discontinuation (29.4%) were most frequently cited. Physicians with junior titles were more likely to select fixed-duration therapy than those with senior titles (odds ratio [OR] 3.48; P = 0.014), suggesting that clinical experience and confidence in treatment safety influence adoption. Regarding precision medicine, although awareness of molecular testing for TP53 (95.4%) and IGHV (81.7%) was high, 88.1% of physicians identified patient financial burden as the primary barrier to completing risk stratification, thereby indirectly hindering the precision implementation of fixed-duration strategies.
Conclusions
This study reveals a marked disconnect between high patient acceptability and low physician adoption of fixed-duration therapy. This divergence reflects competing priorities: patients emphasize treatment-free intervals, whereas physicians weigh safety concerns and reimbursement constraints. Economic burden represents a shared obstacle. Bridging this gap calls for enhanced physician education on safety management, reimbursement optimization to mitigate financial toxicity and ensure testing access, and standardized decision aids to align expectations. Addressing these barriers is essential to advancing patient-centered fixed-duration therapy.
DISCLOSURES
Shenmiao Yang, PhD: No relevant conflicts of interest to declare.